Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Capecitabine + Bevacizumab in Recurrent Glioblastoma
NCT02669173Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Oct 2016
- Primary completion
- Jan 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capecitabine in glioblastoma (GBM), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Change of concentration in circulating MDSCs after treatment with low dose capecitabine at 8 months. Started Oct 2016; status: completed.
02
Drugs
capecitabine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02669173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669173.